Latest:
Dr. Kane on Challenges Facing Genetic Testing in Prostate Cancer
Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses challenges facing genetic testing for patients with prostate cancer.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Christopher Lieu, MD
Latest:
AE Management of Cabozantinib
Panelists discuss how managing cabozantinib’s adverse effects requires proactive patient counseling about expected dose reductions, aggressive supportive care for manageable toxicities like hypertension and diarrhea, frequent early monitoring, and recognition that the median effective dose (40 mg) is lower than the starting dose (60 mg).
Christopher P. Evans, MD
Latest:
Dr. Evans Discusses the Subgroup Analysis Results of the PREVAIL Study
Christopher P. Evans, MD, professor, chairman, Department of Urology, University of California at Davis School of Medicine, UC Davis Comprehensive Cancer Center, discusses the results of an analysis of patients with and without visceral disease defined as liver and/or lung metastases who participated in the PREVAIL study.
Christopher P. Filson, MD, MS
Latest:
New Imaging Strategies for Prostate Cancer Explored
Continuing research will have to evaluate whether combining serum biomarkers or other measurable clinical factors with multiparametric magnetic resonance imaging results can help make negative or inaccurate prostate biopsies a rarity rather than the norm.
Christopher Pietras, MD
Latest:
Dr. Pietras on Palliative Care for Patients With Ovarian Cancer
Christopher J. Pietras, MD, director, Palliative Care, assistant clinical professor, University of California, Los Angeles (UCLA) School of Medicine, discusses palliative care for patients with ovarian cancer.
Christopher Sweeney, MBBS
Latest:
Dr. Sweeney on the Phase III ENZAMET Trial in Metastatic Hormone-Sensitive Prostate Cancer
Christopher Sweeney, MBBS, medical oncologist at the Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute, discusses results of the phase III ENZAMET trial, which looked at standard therapy with or without enzalutamide as a treatment for patients with metastatic hormone-sensitive prostate cancer.
Chukwuemeka V. Ikpeazu, MD, PhD
Latest:
Radiation for Chemo-Sensitization: A Phase II Trial of Cetuximab and Docetaxel With Low-Dose Fractionated Radiation for Recurrent Unresectable Locally Advanced Head and Neck Carcinoma
This study evaluates low dose radiotherapy in combination with docetaxel and cetuximab in patients with recurrent, unresectable squamous cell carcinoma of the head and neck initially treated with definitive chemo-radiation therapy.
Chul S. Ha, MD
Latest:
Combined Radiation Therapy and Checkpoint Inhibition in Lymphoma: A Case Report and Brief Review
The emergence of immune checkpoint inhibitors as an effective treatment strategy is a result of increased understanding of the elaborate relationship between tumor cells, their microenvironment and the host immune response.